Necroptosis in the Pathophysiology of Disease.
Over the past 15 years, elegant studies have demonstrated that under certain conditions, programmed cell death resembles necrosis and depends on a unique molecular pathway with no overlap with apoptosis. This form of regulated necrosis is represented by necroptosis, in which the receptor interacting protein kinase 3 (RIPK3) and its substrate MLKL play a crucial role. With the development of knockout mouse models and molecular inhibitors unique to necroptotic proteins, this cell-death has been found to occur virtually in all tissues and diseases evaluated. There are different immunologic consequences depending on whether cells die through apoptosis or necroptosis. Therefore, distinguishing between these two forms of cell death may be critical during pathological evaluations. In this review, we provide an understanding of necroptotic cell-death and highlight diseases in which necroptosis has been found to play a role. We also discuss the inhibitors of necroptosis and the ways these inhibitors have been used in pre-clinical models of diseases. These two discussions offer an understanding of the role of necroptosis in diseases and will foster efforts to pharmacologically target this unique yet pervasive form of programmed cell-death in the clinic.